2019 Annual Meeting AANextra Sunday by American Academy of Neurology

THE ANNUAL MEETING NEWS DAILY

Sunday, May 5, 2019

Members Vote on Unprecedented Leadership Change at Business Meeting. See Page 4.

THIS MORNING’S PRESIDENTIAL PLENARY SESSION RECOGNIZES FOUR NEUROLOGY GIANTS

Rost

An impressive lineup will address attendees for the premier lectures at this morning’s Presidential Plenary Session from 9:15 a.m. to 12:00 p.m. in the Terrace Ballroom. The hugely popular session will be moderated by Science Committee Chair Natalia S. Rost, MD, MPH, FAAN, FAHA, and open to all meeting attendees. Neuroscience Research Prize recipients will also be recognized during the session. “The Presidential Plenary is the ultimate platform for recognizing some of the biggest names and greatest accomplishments in neurology,” said Rost. “These giants of neurology, who have been at the forefront of their fields for years, will be addressing seminal advances in neuro-oncology, movement disorders, and multiple sclerosis.” Continued on page 15 u

Make Your Way to the Grand Hall for the Grand Experience Make room in your schedule to make your way to the Grand Hall of the Pennsylvania Convention Center each day of the meeting to experience engaging, innovative, creative opportunities in science, networking, and mentoring at the Grand Experience. The NIH Brain Initiative: A Dialogue with the AAN will take place on Monday, and Tuesday will be National Institutes of Health Day in the area. Continued on page 34 u

Today’s Opening Luncheon Kicks off Four Days of Exhibit Hall Happenings Check out the Exhibit Hall today beginning at 11:30 a.m. for the always popular Opening Luncheon that will kick off four days of happenings you won’t want to miss. Running through Wednesday, May 8, from 11:30 a.m. to 4:00 p.m. this year’s hall promises to be anything but traditional. Not only will the area offer countless opportunities to meet, mingle, and learn from pharmaceutical and medical device Continued on page 30 u

Inside Invited Science 14 Today’s Examines Infectious Diseases and Global Health

in the 44 Neuroscience Clinic Sessions Kick Off Today with Childhood Epilepsy

the Latest Research 45 Find at Today’s Poster Session

In Multiple

Sclerosis—

GREY MATTERS, TOO

FIND OUT WHY

Booth 2300

Sunday, May 5 Cover This Morning’s Presidential

Plenary Session Recognizes Four Neurology Giants

Make Your Way to the Grand Hall for the Grand Experience

Today’s Opening Luncheon Kicks off Four Days of Exhibit Hall Happenings

Members Elect Unprecedented Board Slate at Business Meeting

MIT’s Herr Sees End to Disability Through Technological Innovation

10 Trainees: Make the Most of Your Annual Meeting

10 Discover How Stronger Business

24 Registry Grew in Participation,

The Vision of the AAN is to be indispensable to our members.

26 The Best of Philly from Those

The Mission of the AAN is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction.

Value in 2018

Who Know It Best

30 Join New EHR Synapse Online Community

31 NIH Seeks Your Input on BRAIN Initiative’s Strategic Plan

36 Behavioral Interviewing: Tell a

Compelling Story with Your Answer

40 AAN Industry Roundtable Celebrates 25 Years

42 What Are Your Colleagues Saying? 44 Neuroscience in the Clinic Sessions Kick Off Today with Childhood Epilepsy

Contact Information: 201 Chicago Avenue Minneapolis, MN 55415 USA Phone: (800) 879-1960 (Toll Free) or (612) 928-6100 (International) Fax: (612) 454-2744 Email: memberservices@aan.com Website: AAN.com AAN Chief Executive Officer: Catherine M. Rydell, CAE

Managing Editor:

Angela M. Babb, CAE, APR

14 Today’s Experiential Learning

45 Find the Latest Research at

Editor: Tim Streeter Writers: Ryan Knoke, Sarah Parsons Designers: Siu Lee, Andrew Imholte Photography: Will Evans Printing: Phoenix Lithographing Corporation Email: aannews@aan.com

18 2019 Practice Management Webinar

45 Expanded Symposium Offers

AANextra is published by the American Academy of Neurology.

20 Complete Survey, Benefit from

46 Boxed Lunch Menu 46 What Excited You Today at #AANAM?

The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world. “American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.

Administrators Make a Stronger Practice

12 Kick off a Spectacular Week with Tonight’s Philly Spectacular! Area Highlights

Changes Enable Greater Topic Depth Compensation and Productivity Data

23 Momentum of 2018 Advocacy

44 Today’s Invited Science Examines Infectious Diseases and Global Health Today’s Poster Session

Robust Opportunities for Medical Students

Successes Carries into 2019

Daily Reminders SUNDAY, MAY

Education Program Syllabi and Slides Available Online Only Education Program syllabi and slides are available online only at AAN.com/view/syllabi or through the AAN Conferences Mobile App at AAN.com/view/MobileApp.

May 20 Is Deadline to Submit Online Evaluations for Annual Meeting CME Complete your evaluations to get your CME hours by using the AAN Conferences Mobile App at AAN.com/view/MobileApp or by visiting AAN.com/view/CME. CME requests may be made until Monday, May 20, 2019. Transcripts will be emailed approximately six weeks after the meeting. AAN members can also access their transcript via NeuroTracker™ at AAN.com/view/NeuroTracker.

THE ANNUAL

MEETING NEWS

DAILY

Members Vote on

Leadership Unprecedented

Change at Business

Meeting. See Page

5, 2019

PRESIDENTIAL THIS MORNING’S ION RECOGNIZES PLENARY SESS Y GIANTS FOUR NEUROLOG Rost

will address attendees An impressive lineup at this morning’s a.m. to for the premier lectures Session from 9:15 Presidential Plenary The hugely Terrace Ballroom. 12:00 p.m. in the by Science will be moderated popular session MD, MPH, Natalia S. Rost, Committee Chair attendees. open to all meeting will FAAN, FAHA, and Prize recipients Neuroscience Research the session. during also be recognized Plenary is the ultimate “The Presidential some of the biggest platform for recognizing ts in accomplishmen names and greatest of Rost. “These giants neurology,” said forefront of have been at the seminal neurology, who will be addressing their fields for years, movement advances in neuro-oncology, sclerosis.” disorders, and multiple u 15 Continued on page

to the Make Your Way Grand Hall for the ce Grand Experien

schedule to make Make room in your Hall of the your way to the Grand Center each Pennsylvania Convention to experience day of the meeting creative engaging, innovative, science, networking, opportunities in the Grand Experience. and mentoring at A Dialogue with The NIH Brain Initiative: on Monday, and place the AAN will take Institutes of Tuesday will be National area. Health Day in the Continued on page

u 34

Today’s Opening off Luncheon Kicks Four Days of Exhibit Hall Happenings

Hall today beginning Check out the Exhibit the always popular at 11:30 a.m. for that will kick off four Opening Luncheon miss. you won’t want to days of happenings 8, Wednesday, May Running through 4:00 p.m. this year’s from 11:30 a.m. to be anything but traditional. hall promises to offer countless Not only will the area mingle, and learn opportunities to meet, and medical device from pharmaceutical Continued on page

Philadelphia

Inside Today’s Invited Science Examines Infectious Diseases and Global Health

the Neuroscience in Off Clinic Sessions Kick Today with Childhood Epilepsy

Research

the Latest Session 45 Find at Today’s Poster

u 30

The American Academy of Neurology sincerely thanks Phoenix Lithographing Corporation for its outstanding service, steadfast professionalism, and high quality standards, as well as its generous donation of the 2019 Brain Health Fair program guide.

ÑOL EN ESPA SO AL DOR

EVENT PROGRAM

Thursday, May 9, 2019 • 10:00 a.m.–4:00 p.m. Pennsylvania Convention Center

Members Elect Unprecedented Board Slate at Business Meeting History was made by Academy members attending Saturday’s AAN Business Meeting. By voting to elect the nominees for the 2019–2021 AAN and AAN Institute Boards of Directors, they set the stage for Orly Avitzur, MD, MBA, FAAN, to become president in 2021, and women now hold a record four of the six officer positions on the board. President Ralph L. Sacco, MD, MS, FAHA, FAAN; Treasurer Janis Miyasaki, MD, MEd, FRCPC, FAAN; and CEO Catherine M. Rydell, CAE, reported to members on the financial health of the Academy and key successes during 2018. It was a record-setting year for the AAN in several areas, including membership (36,000 members) US neurologist membership retention (96 percent), retention of early career US neurologists (91 percent), and Annual Meeting attendance (more than 14,000). There also were record numbers of medical student members, advanced practice provider members, and international members. Sacco reported the Academy was meeting its strategic goals and that the board, committees, and subcommittees are working well together. He also highlighted the new Joint Coordinating Councils on Equity, Diversity, Inclusion, and Disparities and on Wellness. Among the charges of these councils is to ensure communication and action on these issues across the Academy. The president also cited significant accomplishments in advocacy efforts, including the AAN’s successful delay on E/M reimbursement changes, resulting in a $43 million annual savings in Medicare payment for E/M services starting in 2021; expansion of patient access to telestroke care through passage of the FAST Act; and a total $5 billion increase in NIH funding across fiscal years 2018 and 2019.

BrainandLife.com and was the first year of the quarterly Brain & Life en Espanol edition. All of the AAN’s publications have now been redesigned, with the debut of the revamped Neurology Today ® this past January.

Sacco congratulated Rydell on her 20th year as the AAN’s chief executive officer. Rydell plans to step down in May 2020, and Sacco noted that a search firm has been engaged and recruitment will begin this summer.

Rydell also spoke of the growth of the Axon Registry ®, now up to more than 1,200 participating members, and creation of the new Learning Management System, which delivers a host of free and discounted online education products.

Treasurer Miyasaki reported that in 2018, the AAN had consolidated revenue of $54 million and expenses of $53 million, resulting in an operating increase of $731,000 over 2017. A downturn in advertising revenue was offset by increases in registration/course income and royalties and publishing. Net assets at the end of 2018 were $67 million. During 2018, $.87 of every $1 of membership dues was used to support products and services for members.

Regarding maintenance of certification, Rydell spoke about her participation on the American Board of Medical Specialties (ABMS) Continuing Board Certification: Vision for the Future Commission. The ABMS launched this commission to bring together multiple partners to envision a system of continuing board certification that is meaningful, relevant, and of value, while remaining responsive to the patients, hospitals, and others who expect that physician specialists are maintaining their knowledge and skills to provide quality specialty care. With input from stakeholders across the neurology spectrum, ABMS seeks to establish new, integrated standards for continuing certification by 2020.

After highlighting the AAN’s big advocacy win in delaying changes to E/M reimbursement, Rydell touted record attendance numbers for the 2018 Annual Meeting in Los Angeles and Sports Concussion Conference in Indianapolis. 2018 saw the rebranding of the AAN’s patient and caregiver magazine Neurology Now to Brain & Life® and the website

Sunday, May 5, 2019 • AANextra

To learn more about the AAN’s professional and financial accomplishments last year, read the 2018 Annual Report available online at AAN.com/view/AnnualReport.

2019 Priorities

2019–2021 AAN Board of Directors

Membership and Leadership

Officers

Maintain record membership numbers and retention

President: James C. Stevens, MD, FAAN

Ensure diversity, equity, and inclusion across all of neurology

President Elect: Orly Avitzur, MD, MBA, FAAN

Focus on improving wellness throughout neurology

Vice President: Ann H. Tilton, MD, FAAN

Deliver personalized member experiences Cultivate neurology leaders of tomorrow

Advocacy and Health Policy Ensure patient access to neurologic care Oppose any payment policy that would further

devalue E/M services

Increase drug pricing transparency and access Reduce disparities in health care delivery Expand patient engagement and advocacy

Education and Practice Assure pipeline of neurologists and multidisciplinary

team (APPs)

Educate on gender, race, and equity disparities

across neurology

Expand education in various formats to support

members across lifetime

Expand Axon Registry

Academic Neurology and Science Increase federal research funding and expand

AAN Research Program

Innovate Annual Meeting scientific offerings Support needs of academic neurology departments

Secretary: Carlayne E. Jackson, MD, FAAN Treasurer: Janis M. Miyasaki, MD, MEd, FRCPC, FAAN Past President: Ralph L. Sacco, MD, MS, FAHA, FAAN

Directors Brenda Banwell, MD, FAAN Sarah M. Benish, MD, FAAN Charlene Gamaldo, MD, FAAN James N. Goldenberg, MD, FAAN Jonathan P. Hosey, MD, FAAN Elaine C. Jones, MD, FAAN Shannon M. Kilgore, MD, FAAN Brett M. Kissela, MD, MS, FAAN Thomas R. Vidic, MD, FAAN

Ex Officio (voting) Nicholas E. Johnson, MD, FAAN, Chair, Advocacy Committee Brad C. Klein, MD, MBA, FAAN, Chair, Medical Economics

and Practice Committee

Gregory D. Cascino, MD, FAAN, Chair, Member

Engagement Committee

Robert A. Gross, MD, PhD, FAAN, Editor-in-Chief of

Neurology®

Ex Officio (non-voting) Catherine M. Rydell, CAE, Chief Executive Officer

Engage department chairs and business administrators

2019–2021 AAN Institute Board of Directors The following are additional members of the AAN Institute Board of Directors who do not serve on the AAN Board of Directors.

Officer Charles C. Flippen II, MD, FAAN,

AAN Institute Secretary-Treasurer

Ex Officio (voting) Natalia S. Rost, MD, MPH, FAAN, FAHA,

Chair, Science Committee

Lyell K. Jones, Jr., MD, FAAN, Chair,

Quality Committee

A. Gordon Smith, MD, FAAN, Chair,

Education Committee 

Sunday, May 5, 2019 • AANextra

With hereditary transthyretin-mediated (hATTR) amyloidosis...

Patients and their families face a future of functional decline1-3

Important Safety Information Infusion-Related Reactions (IRRs) In a controlled clinical study, 19% of ONPATTROtreated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache. To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Reduced Serum Vitamin A Levels and Recommended Supplementation ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness). Adverse Reactions The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%). Please see brief summary of full Prescribing Information following this ad.

References: 1. Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013; 8:31. 2. Coutinho P, Martins da Silva A, Lopes Lima JL, et al. Excerpta Medica; 1980:88-98. 3. Vinik EJ, Vinik AI, Paulson JF, et al. J Peripher Nerv Syst. 2014;19:104-119. 4. ONPATTRO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; 2018. 5. Adams D, Coelho T, Obici L, et al. Neurology. 2015;85(8):675-682. 6. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. N Engl J Med. 2018;379(1):11-21. 7. Center for Drug Evaluation and Research. NDA 210922—patisiran—cross-discipline team leader review. U.S. Department of Health and Human Services, Food and Drug Administration; 2018. ONPATTRO is a registered trademark of Alnylam Pharmaceuticals, Inc. © 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR02-USA-00023-012019

ONPATTRO® (patisiran) can reverse polyneuropathy manifestations of the disease4 A novel RNAi-based approach that may transform the future for your patients1,4-6 ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

At 18 months, ONPATTRO demonstrated: Reversal in neuropathy impairment4

Study Design The efficacy of ONPATTRO was demonstrated in a randomized, double-blind, placebo-controlled, multicenter clinical trial in adults with hATTR amyloidosis with polyneuropathy. Patients were randomized to receive ONPATTRO 0.3 mg/kg (N=148) or placebo (N=77) via intravenous infusion once every 3 weeks for 18 months. Primary endpoint: The modified Neuropathy Impairment Score + 7 (mNIS+7) is an objective 304-point assessment of neuropathy that measures cranial nerve function, muscle strength, reflexes, postural blood pressure, quantitative sensory testing, and peripheral nerve electrophysiology. Key secondary endpoint: The Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) scale is a patient-reported assessment that evaluates neuropathy in the following domains: physical functioning/large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy (score range -4 to 136). Select secondary endpoint: The Composite Autonomic Symptom Score 31 (COMPASS 31) is a patient-reported questionnaire that evaluates 6 autonomic domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor (score range 0 to 100).

• Mean change from baseline in mNIS+7 of -6.0 points vs 28.0 with placebo, a treatment difference of -34 points (95% CI: -39.9, -28.1; p<0.001)

Improvement in quality of life4 • Mean change from baseline in Norfolk QoL-DN score of -6.7 points vs 14.4 with placebo, a treatment difference of -21.1 points (95% CI: -27.2, -15.0; p<0.001)

Reduction in autonomic symptoms6,7 • Mean change from baseline in COMPASS 31 of -5.3 points vs 2.2 with placebo, a treatment difference of -7.5 points (95% CI: -11.9, -3.2; p<0.001) CI=confidence interval; RNA=ribonucleic acid; RNAi=RNA interference.

Visit Booth #2401 to find out more.

MIT’s Herr Sees End to Disability Through Technological Innovation When Hugh Herr, PhD, lost both of his lower legs to amputation after a rock climbing accident in 1982, he did not see himself as broken. He thought that technology was broken and inadequate. Today, Herr heads the Biomechatronics group at the MIT Media Lab, creating bionic limbs that emulate the function of natural limbs. In Saturday’s powerful talk, Herr reiterated his belief, stating that basic levels of physiologic function should be a part of our human rights. He said that every person should have the right to live life without disability if they so choose. Herr said these rights can be achieved if we accept that humans are not disabled; our built environment and technologies are broken and disabled. We can transcend disability through technological innovation, he said.

compelling discussion on The Origin of Moral Intuitions beginning at 1:00 p.m. Wednesday. Throughout her successful career, Churchland has contributed to the fields of neurophilosophy, philosophy of the mind, and neuroethics. Her research has centered on the interface between neuroscience and philosophy with a current focus on the association of morality and the social brain. She is a professor emeritus of philosophy at the University of California, San Diego and adjunct professor at the Salk Institute. 

Herr’s moving speech inspired attendees.

Herr

NEW IN

2019

“Dr. Hugh Herr is the ABSOLUTE inspiring and innovative leader of the Bionic Age!,” tweeted Mam Ibraheem, MD, MPH, CPH. Holly Hinson, MD, MCR, FAAN, tweeted, “Incredible thoughts about transcending disability with augmented ability via #technology from Hugh Herr.” The Advancing Medicine: Inspiration and Innovation series continues at 1:00 p.m. on Monday with Mona Hanna-Attisha, MD, MPH, a pediatrician, professor, and public health advocate whose research exposed the Flint water crisis. Her bestselling book, What the Eyes Don’t See: A Story of Crisis, Resistance, and Hope in an American City, is a fascinating account of a shameful disaster that became a tale of activism and hope. A limited number of free books will be available to attendees, as well as additional copies for purchase. The series concludes with Patricia Churchland, BPhil, leading a

Let’s Talk Cannabinoids

Stop by booth #2011 at the AAN annual meeting in Philadelphia, from May 5–8, and learn about the evidence for and against cannabinoids as medicine.

Talk to your patients about cannabinoids with a deeper understanding of the science behind the medicine.

Visit

Evidence-driven medicine

Trainees: Make the Most of Your Annual Meeting Students, residents, and fellows can expect to find programs and events going on all week long that are tailored specifically to their needs and will allow them to gain firsthand access to the latest neurology education and science, hear from renowned experts in their chosen subspecialty area of interest, and make essential connections that will prove invaluable to career advancement. Highlights include:

Trainee Experience

Saturday, May 4–Friday, May 10 The Grand Experience Connect with your peers and physicians to hear about the day’s highlights.

Experiential Learning Areas Saturday, May 4–Friday, May 10 Dynamic and interactive areas that will offer a variety of real-world experiences to engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally.

Futures in Neurological Research Track Saturday, May 4–Friday, May 10

Grow your future career in research with a curated set of courses and learning opportunities that will improve your knowledge and skills. Filter for the track within the AAN Conferences app.

For more information, visit AAN.com/view/AMTrainee.

Chief Resident Leadership Program

Sunday, May 5 / 12:00 p.m.–4:00 p.m. Both current and future neurology chief residents will explore their own leadership potential, learn skills to enhance their success in their leadership role, and develop critical skills for use in this and future leadership roles. This program is designed for the resident poised to lead neurologists who promote the highest quality patient-centered neurologic care and professional development.

Resident Basic Science II: Neuropharmacology

Sunday, May 5 / 1:00 p.m.–5:30 p.m.

Philly Spectacular— at Reading Terminal Market!

Sunday, May 5 / 7:00 p.m.–10:00 p.m. Pre-reserved ticket required. See page 12 for details.

Student Interest Group in Neurology (SIGN) Meeting Monday, May 6 / 7:30 a.m.–9:00 a.m.

Resident Basic Science III: Neuroanatomy: All the Lesions Monday, May 6 / 1:00 p.m.–5:30 p.m.

Reception

Early Career

Monday, May 6 / 6:00 p.m.–9:00 p.m.

Philadelphia Marriott Downtown / Grand Ballroom Network with chairs of neurology departments and their faculty, peers, and AAN leaders; view clerkship/residency/ fellowship opportunities and learn about careers in neurology; and find out how the AAN can help you succeed throughout your neurology career.

Digital Scavenger Hunt Offered daily throughout the week. Visit the Annual Meeting Trainee website page for updates on scheduling.

Poster Hall Tour Held during various poster sessions. Check the Annual Meeting Trainee website page for updates on scheduling.

Discover How Stronger Business Administrators Make a Stronger Practice

If you aren’t able to get to the Experiential Learning Area this week, visit AAN.com/ view/CareTeam to learn more and sign up your business administrators quickly and conveniently online. 

Gene Therapy Reverses MS Symptoms paGe 4

Sunday, May 5, 2019 • AANextra

paGe 9

The Global Burden of Motor Neuron Disease paGe 16

jaNuaRy 10, 2019 | VOluMe 19 | iSSue 1

The cGRp antagonists are here. Now how Do you use Them? The Real-World Experience of Migraine Experts christine lehmann

ince the US Food and Drug Administration (FDA) approved three calcitonin gene-related peptide (CGRP) antagonists in 2018 — erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) — neurologists have begun integrating them into their practice. More CGRP drugs that can prevent and

treat acute headaches are in the pipeline, with FDA approval expected within two years. Designed to prevent chronic and episodic migraines, the CGRPs showed rapid, significant, and long-lasting relief of migraines with minimal adverse effects in clinical trials. Neurology Today interviewed several neurologists specializing in migraines about their recent clinical experience with the drugs, and any concerns that arose. Their experience to date has been

mostly positive, they said, but they did offer several caveats, as well as noteworthy observations from early experiences prescribing them. “This is the first time we have a preventive class of drugs that was created and designed just for the treatment of migraines based on what we now know about migraine pathophysiology,” said Rebecca Erwin Wells, MD, MPH, associate professor of neurology and founder and director of the comprehensive headContinued on page 24 ache program

Migraine specialists agreed that more clinical practice data is needed to better understand the long-term effects and implications of prescribing CGRPs.

passive eeG Detects covert awareness in Severely Brain-injured patients dan hurley

new screening test using electroencephalography (EEG) accurately detected covert consciousness in severely brain-damaged patients who appear clinically unresponsive at the bedside, according to a December 3, 2018, paper published in Current Biology.

Coming 12 years after the first such patients were identified with the use of a functional MRI (fMRI) technique, the new EEG test may eventually make it practical for general neurologists to identify those in nursing homes who are covertly conscious but are currently considered to be unaware of their surroundings, according to an accompanying commentary. At present, only a handful of centers in North America and Europe

have neurologists trained in conducting the costly fMRI exams. Those fMRI exams involve asking patients with disorders of consciousness to follow spoken instructions by imagining that they are playing tennis or walking through their homes, and then seeing if the resulting pattern of brain activity is consistent with the requested imaginary tasks. The new test protocol does not require patients to follow such commands, making

it among the first reports of a purely passive measure of awareness that is correlated with an fMRI-based motor imagery task. Instead, patients simply listen on earphones to spoken language — such as stories and memories about their lives prior to their injury shared by family members — and the pattern of their EEG response is compared to that of normal controls. In the study of 21 severely brainContinued on page 20 injured patients,

Meet Neurology’s Diversity and inclusion “champions”

PerIODICAlS

paGe 12

NeurologyToday (ISSN 1533-7006), an official publication of the American Academy of Neurology, is published twice a month for the Academy by Wolters Kluwer, at 14700 Citicorp Drive, Bldg. 3, Hagerstown, MD 21742. POSTMASTER: Send address changes to Neurology Today, PO Box 1610, Hagerstown, MD 21740. Periodicals Postage Paid at Hagerstown, MD and at additional mailing offices.

LWW_NTY_January 10_19_Layout.indd 1

Therapy Stops Seizures in NORSe

The Official Ne wS SOuRce Of The a MeRicaN acaDeMy Of NeuROlOGy | NeuROlOGy TODay.cOM

ISTOCKPHOTO

While there, you can learn how for only $270 business administrators can receive exclusive, career-strengthening AAN member benefits valued at up to $4,000, such as free access to the AAN’s 2019 Practice Management Webinar

series; publications such as Neurology:® Clinical Practice and Neurology Today ®; significant discounts on registration to the Annual Meeting; free AAN online education resources like NeuroSAE® and NeuroLearn™; and much more. Or, for as little as $115, business administrators can receive all of the aforementioned benefits, excluding the Practice Management Webinar series, Neurology Today (print), and free access to NeuroSAE and NeuroLearn.

ISTOCKPHOTO

Each member of the neurology practice is essential to high-quality patient care. Stop by the Experience the AAN: Make the Most of Your Membership Experiential Learning Area on Arch Street, Level 100, throughout the week to find out how you can give your business administrators an edge with access to the world’s best neurology resources and education to help them better reduce costs and increase revenue for your practice.

24/12/18 11:17 AM

What’s the key to breakthrough Neuro research and treatments? Collaboration. At NewYork-Presbyterian Hospital, we partner with specialists

from Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine to provide care to thousands of neurology and neurosurgery patients. Faculty from both medical schools are at the forefront of conducting research and clinical studies for a wide range of conditions. Recent advances include: Alzheimer’s • A study that uncovered large-scale changes throughout the epigenome of the human Alzheimer’s disease brain, revealing that tau-induced alterations of chromatin structure are more profound than changes attributable to amyloid pathology. • The launch of our new Alzheimer’s Prevention Clinic that combines evidence-based, low-risk interventions with lifestyle modifications that may help to delay, or in some cases possibly prevent, the progression towards dementia. Brain Tumors • The first-ever dose escalation study using convection-enhanced delivery for diffuse intrinsic pontine glioma to bypass the blood-brain barrier and administer a drug directly to the brain stem tumor site. Stroke • Participated in the DEFUSE trial which has shown the benefit of late thrombectomy from 6 to 24 hours past onset of a large vessel occlusive stroke. Because of these innovations and more, our Neurology and Neurosurgery program is ranked #1 in New York and #5 in the nation by U.S. News & World Report.

Learn more at nyp.org/neuroinnovations

New York’s #1 hospital for a reason. Source: New York’s #1 hospital as ranked by U.S. News & World Report 2018-19

Kick off a Spectacular Week with Tonight’s Philly Spectacular! Join your colleagues tonight from 7:00 p.m. to 10:00 p.m. at Reading Terminal Market, adjacent to the Pennsylvania Convention Center. Embrace the city’s rich history from within one of the United States’ largest and oldest public markets, operating since 1893 in a beautiful National Historic Landmark building. Catch up with old friends and colleagues and meet and make new ones while enjoying an incredible selection of locally grown and exotic produce, locally sourced meats and poultry, and the finest seafood, cheeses, baked goods, and confections. Eat, drink, and dance in the street to the sounds of Jellyroll, Philly’s original 12-piece horn party dance band, as they perform a repertoire spanning old-school classics to the newest top 40 hits. The awardwinning ensemble has won over audiences from Madison Square Garden in New York

Sunday, May 5, 2019 • AANextra

City to the White House in Washington, DC. Attendees can also enjoy appetizers, sample local craft beers, participate in trivia for prizes, and play unlimited arcade games at the neighboring Field House sports bar. Pre-reserved gratis and guest tickets will be distributed with your conference badge at Registration. Tickets that are not picked up by 5:30 p.m. today will be released. If you didn’t get an advance ticket for the Philly Spectacular, stop by Registration after 6:00 p.m. to see if there are any unclaimed tickets

available. Additional tickets may be purchased for $115 at Registration. Tickets include all-you-can-eat food, beer/wine/ soda, entertainment, and transportation to and from hotels. All attendees and guests must be wearing the special lanyard to enter. 

INDUSTRY THERAPEUTIC UPDATE FROM AVEXIS A NEW FRONTIER FOR NEUROMUSCULAR DISORDERS: SPOTLIGHT ON GENE THERAPY Wednesday May 8 2019, 7:00 PM for 7:30 PM start* Room: Liberty Ballroom, Philadelphia Marriott Downtown

Faculty:

Perry Shieh, MD, PhD (Chair) Meredith Schultz, MD Christopher Walker, PhD Chris Jenkins, PhD *Dinner to be served at 7:00 PM

The Faculty of experts will explore the latest advances in gene therapy (GT) research and the use of GT in the clinical treatment of neuromuscular diseases, taking the treatment from bench to bedside. Time

Presentation Title

Faculty Member

7:00 – 7:30 PM

Dinner reception

7:30 – 7:35 PM

Welcome and introduction

Perry Shieh, MD, PhD (Chair)

7:35 – 7:55 PM

Gene therapies: a new frontier for neuromuscular disorders

Meredith Schultz, MD

7:55 – 8:15 PM

A focus on adeno-associated virus (AAV) antibodies

Christopher Walker, PhD

8:15 – 8:35 PM

Biosafety considerations for the clinical use of AAVs

Chris Jenkins, PhD

8:35 – 8:45 PM

Panel discussion

All Speakers Facilitated by Chair

8:45 – 8:55 PM

Questions and answers

All Speakers Facilitated by Chair

8:55 – 9:00 PM

Closing remarks

Perry Shieh, MD, PhD (Chair)

In accordance with Federal Law, all food and beverage are reportable. You will have the opportunity to opt-out of food and beverage upon arrival at the Liberty Ballroom, Philadelphia Marriott Downtown This meeting is not part of the AAN Annual Meeting official programming and no CME is given for attendance. This Industry Therapeutic Update is sponsored and organized by AveXis. ©2019 AveXis, Inc. All Rights Reserved.

MED-CON-UNB-00019-US 04/2019

Today’s Experiential Learning Area Highlights HeadTalks Neurology Pictionary 12:00 p.m.–1:00 p.m. Join Bert B. Vargas, MD, FAAN, for this charades-inspired guessing game centered on all things neurology.

Maximize Your Value and Advocacy to Action Tip of the Iceberg: Ultra High-cost Neurology Drugs 1:00 p.m.–1:45 p.m. AAN Board member Nicholas E. Johnson, MD, FAAN, discusses what the AAN is doing to control drug pricing and what you can do for your patients.

Research Corner

Be sure to attend tomorrow’s session:

Updating the NIH BRAIN Initiative: A Dialogue with the AAN Monday, 8:00 a.m.–9:00 a.m., Grand Experience Stage 2

Standing on the Shoulders of Giants 5:15 p.m.–6:15 p.m. Cynthia L. Comella, MD, FAAN, kicks of this series of five neurology giants who share their personal journeys in neurology and how they have contributed to the evolution of the field.

Live Well: Taking Care of Your Patients Starts with Taking Care of You Happiness Hour 5:00 p.m.–5:30 p.m. Join us as we celebrate the unique practices and hobbies our members take part in to nourish and bring them satisfaction in their lives—both in and outside of their neurology practice. Light appetizers and wine will be served.

Sunday, May 5, 2019 • AANextra

Launched in 2014, the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is revolutionizing our understanding of the human brain. Guided by its strategic plan BRAIN 2025: A Scientific Vision, NIH has invested over $950 million to fund over 500 projects at more than 100 research institutions accelerating the development of new technologies to identify all cell types in the brain, map out their circuit connections, observe circuit activity in real time, manipulate circuit function to understand how the brain works, and, ultimately, to treat the many neurological and psychiatric disorders that arise from circuit malfunction. An external scientific working group, the Advisory Committee to the Director of NIH (ACD) BRAIN Initiative Working Group, is reaching out extensively to the research community to assess progress and identify how the Initiative can best invest to realize its vision through the second half of the Initiative. This work group hopes to gain feedback and insight from AAN Annual Meeting attendees into how the BRAIN Initiative can maximize opportunities to meet its audacious goal: understanding how the brain works, and how brain disorders occur.

Navigating Your Career Navigating a Career in Academics 2:00 p.m.–2:45 p.m.

Jennifer Rose Molano, MD, FAAN, and Joseph E. Safdieh, MD, FAAN, will share their experiences navigating the academic environment to start their careers, focusing on negotiation strategies you can employ with your chair to help ensure you have the resources you need to be poised for success.

Experience the AAN Find out how the AAN supports and works for you, and how to better use AAN.com for your specific professional needs.

Innovation Hub Level Up: How Video Games Change the Brain 2:30 p.m.–3:00 p.m. A whole generation is growing up with massive online role-playing games, e-sports competitions, and mobile technology, which prompts controversial questions about addictiveness, impaired development, improved hand-eye coordination, and therapeutic applications. Come join a discussion of the potential neurological impacts of video games.

Mona Bahouth, MD, and Justin T. Jordan, MD, MPH, discussed quality improvement research at the Navigating Your Career Experiential Learning Area.

Medical Improv 3:00 p.m.–3:30 p.m. The first of four sessions focusing on creative ways to improve communication skills. 

This Morning’s Presidential Plenary Session Recognizes Four Neurology Giants continued from cover Presidential Lecture “Neurology: Challenges, Opportunities, and the Way Forward” AAN President Ralph L. Sacco, MD, MS, FAHA, FAAN Miller School of Medicine, University of Miami, Miami, FL

H. Houston Merritt Lecture “Neuronal Ceroid Lipofuscinosis: Natural History Studies in Rare Neurodegenerative Disease” Jonathan W. Mink, MD, PhD, FAAN University of Rochester, Rochester, NY

Sidney Carter Award in Child Neurology Music therapy is being used in the treatment of TBI, PTSD, and other psychological issues in medical military facilities across the country. Renee M. Pazdan, MD, FAAN, and a music therapist demonstrated evidence-based music therapy interventions such as therapeutic singing, instrumental improvisation, and music-assisted relaxation and supportive research, followed by a case presentation by Pazdan on how this technique impacted neurologic patient care in the TBI clinical setting.

“Myelin Plasticity in Health and Disease” Michelle Monje, MD, PhD Stanford University, Stanford, CA

Robert Wartenberg Lecture “Progress in Understanding Progressive MS: From the Microscope to the Bedside” Claudia F. Lucchinetti, MD, FAAN Mayo Clinic, Rochester, MN

Attendees started their morning off with a good laugh, yogic breathing exercises, and some calming mindfulness meditation at the Laughter Yoga session in the Live Well Experiential Learning Area.

What is your "aha" moment from the Presidential Plenary Session? Join the conversation at #AANAM. 

Sunday, May 5, 2019 • AANextra

Visit us at Booth #2345 at the AAN Annual Meeting

Follow the PATH The next step in CIDP

• Learn about our portfolio of Ig products, including the first and only subcutaneous Ig (SCIg) for CIDP maintenance in adults For adults with CIDP stabilized on IVIg

PROVEN CIDP CONTROL Greater Freedom for Everyday Living

• Watch a video of a CIDP patient demonstrating SCIg self-administration • See results from PATH— the largest study in CIDP

Important Safety Information Hizentra is indicated for: • Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older. • Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment. – Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy. For subcutaneous infusion only. WARNING: Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin (Ig) or components of Hizentra (eg, polysorbate 80), as well as in patients with immunoglobulin A deficiency with

antibodies against IgA and a history of hypersensitivity. Because Hizentra contains L-proline as stabilizer, use in patients with hyperprolinemia is contraindicated. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. Thrombosis may occur following treatment with Ig products, including Hizentra. Monitor patients for aseptic meningitis syndrome (AMS), which may occur following treatment with Ig products, including Hizentra. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. In addition, monitor patients for clinical signs of hemolysis or pulmonary adverse reactions (eg, transfusion-related acute lung injury [TRALI]). Hizentra is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated. The most common adverse reactions (observed in ≥5% of study subjects) were local infusion-site reactions, as well as headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, upper respiratory tract infection, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, and nasopharyngitis. The passive transfer of antibodies can interfere with response to live virus vaccines and lead to misinterpretation of serologic test results. Please see the following brief summary of prescribing information for Hizentra, including boxed warning.

Scan your badge at Booth #2345. We’ll contribute to support people with CIDP.

CSL Behring will contribute to the GBS|CIDP Foundation International with every scanned badge. Help us reach our sponsorship goal of $25,000! CSL Behring does not make products indicated for GBS in the US.

$25,000

May is CIDP Awareness Month

Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC. Hizentra® is a registered trademark of CSL Behring AG. Biotherapies for Life® is a registered trademark of CSL Behring LLC. ©2019 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA www.CSLBehring.com www.Hizentra.com HIZ-0838-MAR19

HIZENTRA®, Immune Globulin Subcutaneous (Human), 20% Liquid Initial U.S. Approval: 2010 BRIEF SUMMARY OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HIZENTRA safely and effectively. See full prescribing information for HIZENTRA. WARNING: THROMBOSIS

See full prescribing information for complete boxed warning. • Thrombosis may occur with immune globulin products, including HIZENTRA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. • For patients at risk of thrombosis, administer HIZENTRA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. -----------------------------------INDICATIONS AND USAGE----------------------------------HIZENTRA is indicated for: *Treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older. * Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment. -Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy. For subcutaneous infusion only. -------------------------------DOSAGE FORMS AND STRENGTHS---------------------------0.2 g per mL (20%) protein solution for subcutaneous injection

-------------------------------------CONTRAINDICATIONS-------------------------------------• Anaphylactic or severe systemic reaction to human immune globulin or components of HIZENTRA, such as polysorbate 80 • Hyperprolinemia (type I or II) (HIZENTRA contains the stabilizer L-proline) • IgA-deficient patients with antibodies against IgA and a history of hypersensitivity -------------------------------WARNINGS AND PRECAUTIONS-------------------------------• IgA-deficient patients with anti-IgA antibodies are at greater risk of severe hypersensitivity and anaphylactic reactions. • Thrombosis may occur following treatment with immune globulin products, including HIZENTRA. • Aseptic meningitis syndrome has been reported with IGIV or IGSC, including HIZENTRA treatment. • Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. • Monitor for clinical signs and symptoms of hemolysis. • Monitor for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]) • HIZENTRA is made from human plasma and may contain infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the CreutzfeldtJakob disease (CJD) agent. -------------------------------------ADVERSE REACTIONS--------------------------------------The most common adverse reactions observed in ≥5% of study subjects were local infusion site reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall and nasopharyngitis. To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda. gov/medwatch. ----------------------------------------DRUG INTERACTIONS-----------------------------------The passive transfer of antibodies may interfere with the response to live virus vaccines, and lead to misinterpretation of the results of serological testing. Based on March 2018 revision

2019 Practice Management Webinar Changes Enable Greater Topic Depth The AAN’s popular Practice Management Webinar series has undergone significant changes for 2019. The number of webinars was reduced from past years, but each new webinar is designed to allow for a deeper dive into the subject matter and invite more questions from participants. Each webinar begins with a live, 30-minute session with all course faculty who will introduce the topic and enable registrants to ask questions. Several shorter recorded lectures are posted on learning.aan.com the week following the overview that explore the topic in greater depth, and participants can access these at their convenience. Finally, each topic concludes with a 30-minute live webchat, so participants can ask further questions. Both live components take place at 12:00 p.m. ET and can be accessed at learning.aan.com.

January 15 (recordings available)

August 13

Boss, MD: Managing a Better Practice

Increasing Revenue in Your Practice: Care Models, Ancillary Services, and Other Strategies

J. Todd Barnes, MBA, CMPE; Seth Lefberg

March 12 (recordings available)

David Evans, MBA

Understanding How You Get Paid

October 1

Bruce H. Cohen, MD, FAAN Raissa Villanueva, MD, MPH, FAAN Jeffrey Waugh, MD, PhD Korwyn Williams, MD, PhD

Using Technology for Better Practice Management of Stroke Mark J. Alberts, MD, FAHA Elaine C. Jones, MD, FAAN Lawrence R. Wechsler, MD, FAAN

May 21

November 19

Everything You Wanted to Know About Your Patients but Were Afraid to Ask: Having Difficult Conversations with Patients from Vulnerable Populations

Seeing the Future Clearly: How to Succeed in 2020

Farrah N. Daly, MD, MPH Christopher T. Doughty, MD Justin P. Martello, MD Allan D. Wu, MD, PhD

Joel M. Kaufman, MD, FAAN AAN members can purchase a single webinar series for $99 or purchase a 2019 Practice Management Webinar subscription for only $189—that’s less than $32 per webinar! Webinars are accessible through the AAN Online Learning Center and feature: Convenient live sessions starting at 12:00 p.m. ET On-demand access to recording and presentation slides

if you miss the live event

Convenient on-demand access to shorter, in-depth chapters 2 AMA PRA Category 1 Credits™ per webinar for physicians,

or certificate of completion for non-physicians

Visit AAN.com/view/pmw19 to learn more and register or contact Jessica Nickrand at jnickrand@aan.com. 

Sunday, May 5, 2019 • AANextra

EISAI NEUROLOGY: Committed to Solutions That Transform Societies Eisai is making advances in: Alzheimerâ&#x20AC;&#x2122;s disease

Sleep/wake disorders

LEARN MORE AT

Epilepsy

BOOTH 909 CORP-US2259 April 2019

Complete Survey, Benefit from Compensation and Productivity Data The AAN encourages members to participate in the 2019 Neurology Compensation and Productivity Survey, the largest survey devoted to the neurology specialty. It provides vital information for neurologists, advanced practice providers (APPs), and business administrators to have the tools to negotiate on their own behalf and compare practice benchmarks against peers and other practices. The collected data is secure and de-identified for anonymity. AAN members who respond by May 25 will receive free access to the data via a customizable dashboard, a $600 value. The revamped survey includes new questions on in-demand topics, including on-call compensation and productivity, telemedicine benchmarks, and practice information such as ancillary services, patient wait times, and compensation methods. “The AAN’s Neurology Compensation and Productivity Report is an essential tool for our practice,” said David A. Evans, MBA, chief operating officer of Texas Neurology in Dallas and chair of the AAN’s Practice Management & Technology Subcommittee. “By having comparative data, we have been able to identify variances in several areas to include compensation, call pay, benefits, and RVUs. I also use it to analyze the ratios between metrics, such as compensation-to-RVUs and call pay-to-number of hospital beds. When I filter using varying criteria on the report’s online dashboard, I am always finding actionable data points.”

Neurologists can learn: How other practices perform in cost measures and

benchmarking

How to benchmark compensation and RVUs to others in their

subspecialty

The average payer mixes for neurologic practices The average size of other practices and their employee mix

Advanced practice providers can:

and productivity data for APPs, and deliver the data in a new, interactive and user-friendly online dashboard. Respondents will be able to filter the data to benchmark themselves against others within the same subspecialty, geographic region, practice setting, and practice size. We heard your feedback and have made several changes to the survey this year, making it easier to complete and provide more meaningful data. Improvements include: Compensation and productivity benchmarking for

advanced practice providers specializing in neurology. As important members of the care team, AAN member nurse practitioners, physician assistants, and other advanced practice providers will be included in the survey collection so you can benchmark your compensation and productivity.

Conditional questioning: If a set of questions doesn’t pertain

to you, you can skip past them, making the survey less time consuming to complete.

New, user-friendly dashboard allowing filtering of the data

by subspecialty, geographic region, gender, and more.

Discover key productivity and compensation metrics for APPs

working in neurology

Compare their productivity with other APPs Benchmark the compensation for their work Explore neurology APP salaries using subspecialty data

Business administrators can: Find out how other practices perform in cost measures and

benchmarking

Learn the average size of other practices and their use of

APPs in their employee mix

Discover the payer mix for neurologic practices Benchmark their salary against other practice managers

working in neurologic practice settings

Use a downloadable and savable spreadsheet to import data

on behalf of the neurologists in their practice

More than 1,300 AAN members took the most recent survey in 2017. Based on feedback from previous respondents and several work groups, the new survey has been overhauled to make it faster and easier to complete, obtain compensation

Sunday, May 5, 2019 • AANextra

Did You Know Neurologists’ Compensation Went up by Three Percent from 2015 to 2016? Help us see if this changed in 2018 by completing the Neurology Compensation and Productivity survey.

The following information will be needed when you start the survey: Physician salary spreadsheets, W2s, and/or K1s Physician RVU reports

Visit with Us to Learn More You can learn more and have your questions answered about the Neurology Compensation and Productivity Survey at the Maximizing Your Value Experiential Learning Area, or attend the following sessions:

Financial and accounting report(s) Payer mix analysis Staff and physician benefits reports EHR and billing system reports (charges and collections) Department, school (for academic centers), and

practice reports

The survey takes about 30–60 minutes to complete once you’ve compiled your documentation. The deadline to complete the survey is May 25, 2019.

What Can the AAN’s Compensation and Productivity Survey Do for You? Tuesday, May 7, 2:30 p.m.–3:00 p.m.

in the Innovation Hub Experiential Learning Area

What Is the Neurology Compensation and Productivity Survey, and How Can it Increase My Value? Tuesday, May 7, 5:00 p.m.–5:45 p.m. in the Maximizing Your Value Experiential Learning Area For more information, visit AAN.com/view/BenchmarkReport. If you have questions, email benchmark@aan.com. 

Patient-Centric. Physician Owned. Clinically Advanced. Nationally Recognized.

LEADERS • Recognized as New Jersey’s premier

NEUROLOGISTS

New Jersey – Full Time Summit Medical Group, provide integrated care by Neurology, Neurosurgery, Orthopedic Spine Surgery,

Neurologists with subspecialty fellowship training in Movement Disorders,

• More than 80 locations in seven northern New Jersey counties • •

We are a smoke and drug-free environment. EOE M/F/D/V

apply online at:

INDUSTRY THERAPEUTIC UPDATE FROM BIOGEN:

COGNITIVE AND ETHNO-CULTURAL DIVERSITY IN MS

Join us for this interactive dinner meeting on the advancement of MS care. We will discuss diversity in MS populations and how to optimize cognitive monitoring.